Get startedLog in
    Picture of Alligator Bioscience AB logo

    ATORX — Alligator Bioscience AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Alligator Bioscience Gets FDA Authorization To Start Mitazalimab Optimize-2 Phase 2 Trial

    Picture of Alligator Bioscience AB logoAlligator Bioscience AB
    03/04/2023 07:36
    April 3 (Reuters) - Alligator Bioscience AB  ATORX.ST :
    * ANNOUNCES FDA AUTHORIZATION TO INITIATE MITAZALIMAB
OPTIMIZE-2
PHASE 2 TRIAL IN UROTHELIAL CARCINOMA
    * EXPECTS OPTIMIZE-2 STUDY TO BEGIN IN H1 2024, OR EARLIER,
SUBJECT TO OPERATIONAL FEASIBILITY

Source text for Eikon:  ID:nMFN4dmySP 
Further company coverage:  ATORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))

    Recent news on Alligator Bioscience AB

    See all news